Overview
Spherix’s coverage of emerging gastroenterology indications focuses on evolving markets where a paradigm shift is expected in the coming years.
Services Available
Prepping for the pipeline
-
Celiac Disease (US)
-
Clostridioides Difficile (US)
-
Primary Biliary Cholangitis (US)
-
Eosinophilic Esophagitis (US)
-
Nonalcoholic Fatty Liver Disease/Non alcoholic Steatohepatitis (US)
Service Info
Benchmarking new brand perfomance
-
APT 1011 (Ellodi) in Eosinophilic Esophagitis (US)*
-
Dupixent (Sanofi/Regeneron) in in Eosinophilic Esophagitis (US)*
*Pending approvals and launch
Service Info